Niagen Bioscience Stock Price, News & Analysis

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is a bioscience company in the healthcare sector focused on biotechnology, NAD+ (nicotinamide adenine dinucleotide) science, and healthy-aging research. The company describes itself as the global authority and a trusted pioneer in NAD+ discoveries, dedicated to advancing healthspan through precision science and NAD+-boosting solutions built around its patented ingredient Niagen® (nicotinamide riboside, or NR).

Core focus on NAD+ biology and healthy aging

According to multiple company disclosures and press releases, Niagen Bioscience concentrates on understanding and applying NAD+ biology. NAD+ is described as a vital coenzyme found in every cell of the human body, essential for cellular energy production, DNA repair, metabolism, and overall cellular health. The company highlights that NAD+ levels decline with age and exposure to everyday lifestyle stressors, and that this depletion is a key contributor to age-related changes in health and vitality. Niagen Bioscience positions its work as addressing this decline through NAD+ precursors, particularly nicotinamide riboside.

Niagen® and NAD+ precursor platform

At the center of Niagen Bioscience’s business is Niagen®, its patented form of nicotinamide riboside (NR). Company materials repeatedly describe Niagen as the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen is commercialized in both food-grade and pharmaceutical-grade forms and is protected by a robust patent portfolio that covers NR and other NAD+ precursors. The company reports that its intellectual property estate includes dozens of issued and pending patents worldwide, with a large concentration focused specifically on NR and its derivatives.

Niagen Bioscience has also disclosed that it acquired a comprehensive portfolio of existing patents covering NR and its salt forms from Queen’s University Belfast, consolidating ownership of core composition-of-matter and related patents underpinning NR production, composition, and commercial use. These patents include rights to multiple NR salt forms and methods of making NR and other NAD+ precursors across multiple jurisdictions.

Consumer products: Tru Niagen® and Tru Niagen® Beauty

Niagen Bioscience delivers Niagen as the principal dietary ingredient in its consumer supplement line Tru Niagen®. Company communications state that Tru Niagen is the number one NAD+ boosting oral supplement in the United States, based on revenue data from a large U.S. e-commerce marketplace over a defined historical period. Tru Niagen is positioned as a science-backed nutritional supplement for cellular health and healthy aging, available through the company’s direct-to-consumer website and through global retail and distribution partners.

The company has also launched Tru Niagen® Beauty, described as the first NAD+ skincare supplement in the U.S. featuring Niagen. Tru Niagen Beauty is presented as a cellular-first beauty product designed to support skin elasticity and the appearance of hair, skin, and nails. It combines Niagen with a blend of clinically studied ingredients such as astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E, with the stated goal of nourishing beauty from within while complementing core Tru Niagen products.

Clinical-grade offerings: Niagen Plus™ IV and injections

Beyond consumer supplements, Niagen Bioscience develops and commercializes pharmaceutical-grade Niagen® under the Niagen Plus™ brand. These offerings include intravenous (IV) and injectable Niagen products that are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and made available exclusively at clinics with a prescription. The company reports that Niagen IV and injections are offered at hundreds of clinics nationwide, including numerous iCRYO wellness centers, and are intended for individuals seeking NAD+-boosting therapies to support cellular health, recovery, performance, and healthy aging.

Company communications describe Niagen IV as a clinically validated intravenous solution for supporting NAD+ levels, and reference a pilot clinical study in which Niagen IV outperformed NAD+ IV on measures such as tolerability, infusion time, and increases in whole blood NAD+ levels. Niagen Bioscience contrasts Niagen with direct NAD+ supplementation, noting that NAD+ itself is not considered bioavailable in the same way and that oral or intravenous NAD+ has not been well studied in humans.

Research, clinical evidence, and scientific collaborations

Niagen Bioscience emphasizes its scientific orientation and research infrastructure. The company states that Niagen is supported by more than 40 peer-reviewed human clinical studies, over 500 published scientific papers, and more than 50 patents worldwide. It highlights collaborations with independent investigators from universities and research institutions around the globe, and notes that its team includes world-renowned scientists and advisors in fields such as metabolism, brain health, and aging.

The company has reported results from a randomized, double-blind, placebo-controlled clinical trial using Niagen in individuals with long COVID (post-acute sequelae of SARS-CoV-2 infection). According to the published summary, Niagen supplementation in this study significantly increased NAD+ levels and showed within-group improvements from baseline in measures such as fatigue, sleep quality, depression, and executive functioning, while between-group differences versus placebo were not statistically significant. Niagen Bioscience presents this as evidence that restoring NAD+ is a measurable biological response and a potential avenue for further research in conditions of metabolic and cellular stress.

Digital and educational platforms: AboutNAD®

In addition to products, Niagen Bioscience operates AboutNAD®, described as a centralized educational resource and research database focused on NAD+ biology. The platform curates peer-reviewed literature, scientific explainers, and expert perspectives on NAD+ and NAD+ precursors, with a particular emphasis on nicotinamide riboside. It offers categorized research, advanced search tools, and educational content aimed at consumers, clinicians, and researchers who want to understand the published science behind NAD+ and healthy aging.

Business activities and revenue drivers

Company filings and press releases indicate that Niagen Bioscience generates revenue through several related activities:

• Sales of Tru Niagen-branded consumer dietary supplements through direct-to-consumer channels and retail and distribution partners.
• Supply of food-grade Niagen as a raw material ingredient to manufacturers of consumer products.
• Commercialization of pharmaceutical-grade Niagen Plus IV and injectable products through U.S. FDA-registered 503B outsourcing facilities and clinic networks.
• Sales of natural product fine chemicals (phytochemicals) and related research and development services.

In investor communications, the company has also discussed e-commerce momentum, new business-to-business partnerships, and expansion of clinical distribution networks as contributors to its growth outlook.

Intellectual property and supply agreements

Niagen Bioscience’s strategy places significant emphasis on intellectual property protection around NAD+ precursors. The company’s patent portfolio covers NR, NR salt forms, and other NAD+ precursors, including composition-of-matter patents and methods of making these molecules. Through an assignment agreement with Queen’s University Belfast, Niagen Bioscience has become the sole owner of key NR patents that were previously jointly owned or licensed, and it has obtained a release from prior royalty and payment obligations under earlier agreements.

The company has also entered into a supply agreement under which a third-party manufacturer exclusively supplies nicotinamide-beta-riboside chloride (NRCL) to Niagen Bioscience, subject to defined specifications and minimum purchase commitments. The supplier is restricted from selling NRCL to other parties and must notify Niagen Bioscience of any new business inquiries relating to NRCL. The agreement includes provisions for potential future licensing of manufacturing patents under certain conditions.

Capital markets activity and shareholder programs

Niagen Bioscience is listed on NASDAQ under the ticker symbol NAGE. The company has disclosed a share repurchase program authorizing the repurchase of up to a specified dollar amount of its common stock over a multi-year period, with repurchases to be made at management’s discretion in accordance with applicable securities laws. The authorization may be modified, suspended, or terminated by the board of directors and does not obligate the company to repurchase a particular number of shares.

At its annual meeting, the company’s stockholders have approved amendments to its equity incentive plan to increase the number of shares available for issuance, as well as an employee stock purchase plan that allows eligible employees to acquire shares through payroll deductions at a discount to market price, subject to plan limits and terms.

Positioning within biotechnology and healthy-aging markets

Within the broader biotechnology and healthy-aging landscape, Niagen Bioscience presents itself as a company focused on translating cellular and metabolic research into practical NAD+-boosting products. Its activities span consumer health supplements, clinical-grade IV and injectable therapies, ingredient supply, and educational initiatives. The company’s emphasis on peer-reviewed science, clinical trials, and patent protection is central to how it describes its differentiation in the NAD+ category.

Frequently Asked Questions about Niagen Bioscience, Inc. (NAGE)

• What does Niagen Bioscience, Inc. do?
  Niagen Bioscience is a bioscience company focused on NAD+ science and healthy-aging research. It develops, manufactures, and commercializes NAD+-boosting products built around its patented nicotinamide riboside ingredient Niagen®, including consumer supplements, pharmaceutical-grade IV and injectable formulations, and ingredient supply for other manufacturers.
• What is Niagen®?
  Niagen is Niagen Bioscience’s patented form of nicotinamide riboside (NR), which the company describes as the most efficient, well-researched, high-quality, and legal NAD+ booster available. It is used as the core ingredient in Tru Niagen supplements and Niagen Plus IV and injectable products and is protected by a broad patent portfolio.
• How does Niagen Bioscience participate in the consumer supplement market?
  The company offers Tru Niagen, a consumer dietary supplement that uses Niagen as its principal ingredient and is marketed for cellular health and healthy aging. Tru Niagen is sold through the company’s direct-to-consumer website and through retail and distribution partners, and has been described by the company as the number one NAD+ boosting oral supplement in the United States over a defined historical period.
• What is Tru Niagen® Beauty?
  Tru Niagen Beauty is a beauty-focused supplement launched by Niagen Bioscience that combines Niagen with clinically studied ingredients such as astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E. It is designed to support skin elasticity and the appearance of hair, skin, and nails while complementing core Tru Niagen products.
• What are Niagen Plus™ IV and injections?
  Niagen Plus is the company’s pharmaceutical-grade Niagen platform, which includes intravenous (IV) and injectable formulations. These products are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available only at clinics with a prescription. They are intended for individuals seeking NAD+-boosting therapies delivered in a clinical setting.
• How strong is Niagen Bioscience’s intellectual property position?
  Niagen Bioscience reports a robust patent portfolio with numerous issued and pending patents worldwide covering Niagen (NR), NR salt forms, and other NAD+ precursors. Through an assignment agreement with Queen’s University Belfast, the company has become the sole owner of core patents related to NR production, composition, and use, including composition-of-matter patents for multiple NR salt forms.
• What kind of research supports Niagen and the company’s products?
  According to company disclosures, Niagen is supported by more than 40 peer-reviewed human clinical studies and over 500 published scientific papers related to NAD+ science. Niagen Bioscience collaborates with independent investigators at universities and research institutions and has reported results from a randomized controlled trial of Niagen supplementation in individuals with long COVID, which demonstrated increased NAD+ levels and within-group improvements in several symptoms.
• What is AboutNAD® and how is it related to Niagen Bioscience?
  AboutNAD is a digital platform developed by Niagen Bioscience that serves as an educational resource and research library on NAD+ biology. It aggregates peer-reviewed studies, expert commentary, and explanatory articles, with a focus on nicotinamide riboside and its role in healthy aging, for audiences that include consumers, healthcare professionals, and scientists.
• How does Niagen Bioscience work with clinics and wellness centers?
  Through its Niagen Plus IV and injectable products, Niagen Bioscience supplies pharmaceutical-grade Niagen formulations to clinics via U.S. FDA-registered 503B outsourcing facilities. The company has reported that these products are available at hundreds of clinics nationwide, including numerous iCRYO locations, aligning its NAD+-boosting therapies with wellness and longevity-focused service providers.
• How is Niagen Bioscience’s stock traded?
  Niagen Bioscience’s common stock trades on the NASDAQ exchange under the ticker symbol NAGE. The company has disclosed a share repurchase program authorizing the repurchase of a specified amount of its outstanding common stock over a defined period, subject to market conditions and applicable regulations.